Literature DB >> 6693798

The influence of aminoglycoside antibiotics on the in vitro function of rat liver ribosomes.

M O Loveless, S J Kohlhepp, D N Gilbert.   

Abstract

There are few studies of the influence of aminoglycoside antibiotics on the ribosomes of higher eukaryotic organisms. To this end, cytoplasmic ribosomes were prepared from rat liver. In vitro, poly(U)-directed ribosome protein synthesis was studied in the presence and absence of selected aminoglycosides. Misreading of poly(U) was also assessed. Consistent with earlier studies using different sources of ribosomes, paromomycin inhibited cell-free protein synthesis and caused poly(U) misreading. In contrast to the findings of other studies in cell-free ribosomes of eukaryotic organisms, netilmicin, tobramycin, and neomycin were most active in inhibiting protein synthesis, and gentamicin C2 and neomycin caused appreciable misreading. Thus the previous suggestion that a paromamine fragment (found in paromomycin) might be a structural requirement for in vitro inhibition of protein synthesis and misreading is not substantiated by the results in rat liver ribosomes. Commercial gentamicin C is a mixture of gentamicins C1, C1a, and C2. Despite nearly identical chemical structures, the three constituents displayed greatly different propensities for inducing poly(U) misreading. C2 was the most active, followed by C1a. In summary, selected aminoglycoside antibiotics caused inhibition and mistranslation of poly(U) messenger in an in vitro ribosome system prepared from rat liver. These effects were not limited to paromamine-containing aminoglycoside antibiotics. Gentamicin C2 caused much more poly(U) misreading than the other two constituents of the gentamicin C complex.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693798

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  4 in total

1.  Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis.

Authors:  Sigrid E Myrdal; Katherine C Johnson; Peter S Steyger
Journal:  Hear Res       Date:  2005-06       Impact factor: 3.208

2.  Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Laurence Viollet; Jerry R Mendell
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 3.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599

4.  Cellular toxicity of aminoglycoside antibiotics in G418-sensitive and -resistant LLC-PK1 cells.

Authors:  M Takano; M Okuda; M Yasuhara; R Hori
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.